Merck makes big changes at the top
pharmafile | October 1, 2013 | News story | Medical Communications, Sales and Marketing | Merck, Merck Serono
Merck has reshuffled its leadership as Belén Garijo is appointed to be its new president and chief executive of Merck Serono, and Stefan Oschmann is made head of Pharmaceuticals in charge of Consumer Health, Allergopharma and Biosimilars.
Additional management changes at Merck Serono include the appointment of Annalisa Jenkins as head of Global Research & Development, and Thierry Hulot as head of Global Manufacturing and Supply.
Garijo who is currently the chief operating officer at Merck Serono (the biopharmaceutical division of Merck) will succeed Oschmann, who is to focus on developing the Merck Serono and Consumer Health divisions, as well as the Allergopharma and Biosimilars units.
“Following our transformational journey over the past two years, we have reached a critical juncture with accelerated profit growth at Merck Serono and a successful re-focusing of our Consumer Health division,” Oschmann said.
“I’m absolutely convinced that with today’s management and organisational changes we will be able to fully leverage the growth potential in our pharmaceutical businesses by focussing on fast-growing areas such as the emerging markets and the global allergy market or the rapidly evolving biosimilars market.
“At Merck Serono, we are proud to have in Belén Garijo one of the most successful leading women in our industry, who – with her broad leadership experience spanning medical, strategic, and commercial roles – will be able to take Merck’s largest division to the next level.”
The firm has also appointed Dr Annalisa Jenkins, currently head of Global Development and Medical, as head of Global Research & Development.
Generating total revenues of €6.4 billion in 2012, Merck Serono is the largest division of Merck. Overall, its pharma businesses accounted for around 60% of total revenues and 58% of EBITDA pre one-time items last year.
Brett Wells
Related Content
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …
CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …
